Patents by Inventor Sang Eun Chae
Sang Eun Chae has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230123569Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.Type: ApplicationFiled: December 1, 2022Publication date: April 20, 2023Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
-
Patent number: 11548883Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.Type: GrantFiled: May 15, 2018Date of Patent: January 10, 2023Assignee: LegoChem Biosciences, Inc.Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
-
Publication number: 20220226496Abstract: The present invention relates to a ligand-drug conjugate including a ligand; a linker that is connected to the ligand by a covalent bond and has a tris structure represented by a specific structural formula; and an active agent connected to the linker by a covalent bond. In the ligand-drug conjugate, the active agent is bound by the tris structure of the linker, and thus a greater number of active agents can be connected through one linker. Accordingly, a greater number of active agents per antibody binding can be delivered to the target cell, and the drug and/or toxin can stably reach the target cell and effectively exert the drug efficacy.Type: ApplicationFiled: April 29, 2020Publication date: July 21, 2022Inventors: Ho Young SONG, Yun-Hee PARK, Sang Eun CHAE, Ju Yuel BAEK, Kyung Eun PARK, Ju Young LEE, Su In LEE, Jeiwook CHAE, Chang Sun LEE, Yong Zu KIM
-
Publication number: 20220096641Abstract: The present invention relates to a novel pyrrolobenzodiazepine dimer compound or a pharmaceutically acceptable salt thereof, a ligand-drug conjugate compound thereof, or a composition containing the same and therapeutic use of the same as an anticancer agent. The pyrrolobenzodiazepine dimer compound according to the present invention exhibits anticancer activity equivalent to or superior to that of existing anticancer agents when being applied to a ligand-drug conjugate as a drug and administered as well as exhibits low activity and greatly diminished toxicity in the free toxin form and thus has a significantly improved therapeutic index. Hence, the pyrrolobenzodiazepine dimer compound is highly industrially applicable in that targeting of proliferative diseases such as cancer is possible, specific treatment of the proliferative diseases is possible, the drug efficacy can be maximized, and the expression of side effects can be minimized.Type: ApplicationFiled: January 3, 2020Publication date: March 31, 2022Inventors: Ho Young SONG, Juyuel BAEK, Sung Min KIM, Hyoung Rae KIM, Hyeun Joung LEE, Ju Young LEE, Kun Jung LEE, Yun-Hee PARK, Chang Sik PARK, Hwan Hee OH, Jihye OH, Jeiwook CHAE, Yong Zu KIM, Sang Eun CHAE, Hyunmin RYU, Nara HAN, Min Ji CHOI
-
Patent number: 10961242Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.Type: GrantFiled: February 6, 2020Date of Patent: March 30, 2021Assignee: LegoChem Biosciences, Inc.Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
-
Publication number: 20200407350Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.Type: ApplicationFiled: May 15, 2018Publication date: December 31, 2020Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
-
Publication number: 20200172542Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same. The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.Type: ApplicationFiled: February 6, 2020Publication date: June 4, 2020Inventors: Dae Yon Lee, Sang Eun Chae, Eun Mi Jung, Eun Hye Yang, Yoon Jeong Choi, Chul-Woong Chung, Ju Hyun Shin, Yun Ki Kim, Hyun Jin Kwon, Jeong Hee Ryu, Eun Hye Ban, Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae
-
Patent number: 9988372Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.Type: GrantFiled: July 18, 2014Date of Patent: June 5, 2018Assignees: GREEN CROSS CORPORATION, LEGOCHEM BIOSCIENCES, INC.Inventors: Soongyu Choi, Jungsub Choi, So-Hyun Yoon, Yoo Hoon Kim, Jae Yeon Kim, Suk Ho Lee, Young Lag Cho, Ho Young Song, Dae Yon Lee, Sung Yoon Baek, Sang Eun Chae, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Publication number: 20170152251Abstract: The present invention relates to a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and a pharmaceutical composition containing the same. The novel crystalline form of a compound according to the present invention exhibits excellent stability even in high-temperature and humidity environments, and thus can be favorably used to prevent or treat diseases, such as thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, and thromboembolism.Type: ApplicationFiled: July 18, 2014Publication date: June 1, 2017Applicants: GREEN CROSS CORPORATION, LEGOCHEM BIOSCIENCES,INC.Inventors: Soongyu CHOI, Jungsub CHOI, So-Hyun YOON, Yoo Hoon KIM, Jae Yeon KIM, Suk Ho LEE, Young Lag CHO, Ho Young SONG, Dae Yon LEE, Sung Yoon BAEK, Sang Eun CHAE, Tae Kyo PARK, Sung Ho WOO, Yong Zu KIM
-
Patent number: 9630977Abstract: The present invention relates to novel cephalosporin derivatives represented by X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.Type: GrantFiled: November 30, 2012Date of Patent: April 25, 2017Assignee: Legochem Biosciences, Inc.Inventors: Young Lag Cho, Joung Yul Yun, Sang Eun Chae, Chul Soon Park, Hyang Sook Lee, Kyu Man Oh, Hye Jin Heo, Dae Hyuck Kang, Young Jae Yang, Hyun Jin Kwon, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Patent number: 8846669Abstract: Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.Type: GrantFiled: March 29, 2012Date of Patent: September 30, 2014Assignee: Legochem Biosciences, Inc.Inventors: Young Lag Cho, Sung Yoon Baek, Sang Eun Chae, Sun Young Kim, Hong Bum Lee, Hyang Sook Lee, Kyuman Oh, Hye Jin Heo, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Publication number: 20140179691Abstract: Disclosed is a novel oxazolidinone derivative represented by Formula 1 above, in particular, a novel oxazolidinone compound having a cyclic amidoxime or cyclic amidrazone group. In Formula 1, R and Q are the same as defined in the detailed description. In addition, disclosed is a pharmaceutical composition for an antibiotic which includes the novel oxazolidinone derivative of Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an active ingredient. The novel oxazolidinone derivative, the prodrug thereof, the hydrate thereof, the solvate thereof, the isomer thereof, and the pharmaceutically acceptable salt thereof have broad antibacterial spectrum against resistant bacteria, low toxicity and strong antibacterial effects against Gram-positive and Gram-negative bacteria and thus may be effectively used as antibiotics.Type: ApplicationFiled: March 29, 2012Publication date: June 26, 2014Applicant: LEGOCHEM BIOSCIENCES, INC.Inventors: Young Lag Cho, Sung Yoon Baek, Sang Eun Chae, Sun Young Kim, Hong Bum Lee, Hyang Sook Lee, Kyuman Oh, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim, Hye Jin Heo
-
Patent number: 8754210Abstract: Disclosed are: a method for preparing a 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}-methyl)thiophene-2-carboxamide derivative, which is a inhibitor of blood coagulation factor Xa, in a high purity and yield; and a novel intermedicate used therein.Type: GrantFiled: July 7, 2010Date of Patent: June 17, 2014Assignees: Green Cross Corporation, Legochem Bioscience Ltd.Inventors: Young Lag Cho, Sang Eun Chae, Seong Jin Kim, Ho Young Song, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim, Jinhwa Lee, Suk Ho Lee
-
Patent number: 8703939Abstract: Provided are a method for preparing (R)-3-(3-fluoro-4-(1-methyl-5, 6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl) oxazolidin-2-one derivatives, which are oxazolidinone antibiotic compounds having a cyclic amidrazone group, represented by Chemical Formula 1, and intermediates thereof, and uses 3,4-difluoro-4-nitrobenzen as a starting material. According to the preparation method of the present invention, (R)-3-(3-fluoro-4-(1-methyl-5, 6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl) oxazolidin-2-one derivatives, which are useful as oxazolidinone antibiotics, can be prepared in high purity and high yield in a simpler manner than conventional methods.Type: GrantFiled: March 8, 2011Date of Patent: April 22, 2014Assignee: Legochem Biosciences, Inc.Inventors: Young Lag Cho, Sung Yoon Baek, Sang Eun Chae, Hong Bum Lee, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Patent number: 8372844Abstract: The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.Type: GrantFiled: April 24, 2012Date of Patent: February 12, 2013Assignee: Korea Research Institute of Chemical TechnologyInventors: Jae Yang Kong, Woo-Kyu Park, Heeyeong Cho, Daeyoung Jeong, Gildon Choi, Hun Yeong Koh, Sang Hee Kim, Ae Nim Pae, Yong Seo Cho, Joo Hwan Cha, Hyunah Choo, Sang Eun Chae, Hee-Yoon Lee
-
Publication number: 20130005967Abstract: Provided are a method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives, which are oxazolidinone antibiotic compounds having a cyclic amidrazone group, represented by Chemical Formula 1, and intermediates thereof, and uses 3,4-difluoro-4-nitrobenzen as a starting material. According to the preparation method of the present invention, (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives, which are useful as oxazolidinone antibiotics, can be prepared in high purity and high yield in a simpler manner than conventional methods.Type: ApplicationFiled: March 8, 2011Publication date: January 3, 2013Applicant: LEGOCHEM BIOSCIENCES, INC.Inventors: Young Lag Cho, Sung Yoon Baek, Sang Eun Chae, Hong Bum Lee, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Patent number: 8329684Abstract: The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. Compounds of the present invention are effective ingredients for the broad spectrum of antibiotic resistance, exhibit low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.Type: GrantFiled: May 8, 2012Date of Patent: December 11, 2012Assignee: Legochem Biosciences, Inc.Inventors: Young Lag Cho, Joung Yul Yun, Sang Eun Chae, Chul Soon Park, Hyang Sook Lee, Kyu Man Oh, Hye Jin Kang, Dae Hyuck Kang, Young Jae Yang, Hyun Jin Kwon, Tae Kyo Park, Sung Ho Woo, Young Zu Kim
-
Publication number: 20120264727Abstract: The present invention relates to novel cephalosporin derivatives represented by Chemical Formula 1. Wherein, X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.Type: ApplicationFiled: May 8, 2012Publication date: October 18, 2012Applicant: Legochem Biosciences, Inc.Inventors: Young Lag CHO, Hye Jin HEO, Kyu Man OH, Hyang Sook LEE, Chul Soon PARK, Sang Eun CHAE, Joung Yul YUN, Hyun Jin KWON, Young Jae YANG, Dae Hyuck KANG, Yong Zu KIM, Sung Ho WOO, Tae Kyo PARK
-
Patent number: 8288423Abstract: The present invention relates to novel oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof, and processes for preparing the same, and pharmaceutical compositions comprising the same. The oxazolidinone derivatives with cyclic amidines, and prodrugs, hydrates, solvates, isomers and pharmaceutically acceptable salts thereof can be usefully employed as an anticoagulant for treating thromboembolism and tumors via inhibition of coagulation factor Xa.Type: GrantFiled: May 9, 2008Date of Patent: October 16, 2012Assignee: Legochem Bioscience Ltd.Inventors: Young Lag Cho, Ho Young Song, Dae Yon Lee, Sung Yoon Baek, Sang Eun Chae, Sang Hui Jo, Yeon Ok Kim, Hyang Sook Lee, Ju Hyun Park, Tae Kyo Park, Sung Ho Woo, Yong Zu Kim
-
Publication number: 20120209001Abstract: The present invention relates to a novel piperazinyl-propyl-pyrazole derivative, a method of its preparation and a pharmaceutically acceptable composition comprising the same. The novel piperazinyl-propyl-pyrazole derivative of the present invention has superior selective affinity for dopamine D4 receptor, can effectively inhibit psychotic behavior (cage climbing) induced by apomorphine, and has relatively low adverse effects in mouse rotarod test. Therefore, it can be developed as a therapeutic agent for the treatment and prevention of central nervous system (CNS) disorders, in particular, schizophrenia, attention deficit hyperactivity disorder, depression, stress diseases, panic disorder, phobia, obsessive-compulsive disorder, posttraumatic stress disorder, cognitive disorder, Alzheimer's disease, Parkinson's disease, anxiety, paraphrenia, mania, seizure disorder, personality disorder, migraine, drug addiction, alcohol addiction, obesity, eating disorder, and sleeping disorder.Type: ApplicationFiled: April 24, 2012Publication date: August 16, 2012Applicant: KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGYInventors: Jae Yang KONG, Park Woo-Kyu, Heeyeong CHO, Daeyoung JEONG, Gildon CHOI, Hun Yeong KOH, Sang Hee KIM, Ae Nim PAE, Yong Seo CHO, Joo Hwan CHA, Hyunah CHOO, Sang Eun CHAE, Hee-Yoon LEE